All

Inspire Medical Systems Clarifies Coding for Inspire V

The transition is expected to reduce professional fees and potentially impact procedure volume.

All

Inspire Reports 33% Year-over-Year Revenue Growth

In its Q3 results, Inspire Medical recapped highlights, including expanded therapy centers, FDA approval for its latest device, and publication of long-term safety data.

All

Inspire Recalls Key Component of Neurostimulator Therapy for OSA

The recall addresses a defect in a subset of Inspire IV implantable pulse generators that may cause malfunctions and necessitate revision surgery for patients.

Neurostimulator Offers Relief to Young Man with Down Syndrome and OSA

May 15, 2024 | Neurostimulators

Nick Lopez, 20, found relief from OSA after receiving Inspire therapy, now FDA-approved for Down syndrome patients as young as 13. Other neurostimulators are in the pipeline.

Inspire Revenue Jumps as Sleep Apnea Therapy Awareness Grows

May 10, 2024 | Neurostimulators

Inspire reported a 28% year-over-year revenue growth in Q1, driven in part by increased awareness of its Inspire therapy for sleep apnea.

Over 60,000 Patients Treated With Inspire Therapy for Sleep Apnea

Feb 12, 2024 | Neurostimulators

Inspire Medical reported in its fourth-quarter earnings that it surpassed 60,000 patients treated with its Inspire neurostimulation therapy for obstructive sleep apnea as of the end of 2023.

Inspire Appoints New Board Chair

Feb 5, 2024 | Evolving Responsibilities

Inspire Medical Systems announced the appointment of chief executive officer Timothy P. Herbert to the additional role of board chair.

Inspire Reports Strong Preliminary Q4 and 2023 Revenue

Jan 10, 2024 | Financial

Inspire announced strong preliminary results for the fourth quarter and full year 2023 and provided its initial full-year 2024 guidance.

Inspire Medical Faces Class Action Lawsuit for Alleged Securities Fraud

Dec 27, 2023 | Laws & Regulations

The lawsuit alleges that Inspire provided misleading information about its Acceleration Program, leading to significant investor losses.

Inspire to Share Data on OSA Neurostimulator Therapy at Upcoming Meetings

Sep 26, 2023 | Neurostimulators, Obstructive Sleep Apnea

Inspire Medical announced upcoming presentations and events highlighting its neurostimulator therapy for obstructive sleep apnea at the International Surgical Sleep Society and American Academy of Otolaryngology meetings.

Series of Regulatory Developments Define Inspire’s Q2 Landscape

Aug 2, 2023 | FDA, Neurostimulators, Obstructive Sleep Apnea

Inspire Medical Systems Inc reported second-quarter business results, marked by a series of US Food and Drug Administration regulatory approvals and submissions.

Improving Care for Children with Down Syndrome and Sleep Apnea

Jun 30, 2023 | Age, Home Apnea Testing, Neurostimulators, Obstructive Sleep Apnea

Sleep apnea is common in children with Down syndrome. Sleep experts weigh in on what’s new in diagnosing and treating this patient population.

Inspire’s Q1 Business Results Highlight Progress in Sleep Apnea Therapy

May 3, 2023 | Neurostimulators, Obstructive Sleep Apnea

Inspire Medical Systems Inc, a medical technology company focused on the development of solutions...

Inspire Receives Reimbursement in Belgium for Sleep Apnea Therapy

Mar 14, 2023 | Neurostimulators, Obstructive Sleep Apnea

The reimbursement approval provides a pathway to open additional Inspire implanting centers in Belgium, while expanding access to care, according to Inspire Medical Systems.